ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and treatment"

  • Abstract Number: 2029 • 2014 ACR/ARHP Annual Meeting

    Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-Sectional Study

    Helga Radner1,2, Kazuki Yoshida3,4, Ihsane Hmamouchi5, Maxime Dougados6,7, Josef Smolen8 and Daniel H Solomon9, 1Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, Kamogawa, Japan, 4Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, 5Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, 6Descartes University, Cochin Hospital, Paris, France, 7INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, 8Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 9Rheumatology, Brigham and Women's Hospital, Boston, MA

    Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-sectional StudyBackground/Purpose The presence of multimorbidity could lead to less intensive treatment of RA.…
  • Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting

    Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses

    Dirkjan van Schaardenburg1, Mairead Murphy2, Yuan Gui2, Samina Turk3, Walter P. Maksymowych4 and Anthony Marotta5, 1Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, 2Augurex Life Sciences Corp., North Vancouver, BC, Canada, 3Reade, Amsterdam, Netherlands, 4Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada, 51423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada

    Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…
  • Abstract Number: 1847 • 2014 ACR/ARHP Annual Meeting

    Effect of Disease Duration on Clinical Outcomes in Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate in the Preserve Study

    Josef Smolen1, David Collier2, Annette Szumski3, Heather Jones4 and Lisa Marshall5, 1PsAID taskforce, EULAR, Zurich, Switzerland, 2Amgen, Inc., Thousand Oaks, CA, 3Specialty Care, Pfizer Inc., Collegeville, PA, 4Inflammation & Immunology, Pfizer Inc., Collegeville, PA, 5Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA

    Background/Purpose Previous studies evaluating various treatment strategies indicate that disease duration is a key determinant of outcomes in rheumatoid arthritis (RA). While data suggest that…
  • Abstract Number: 1540 • 2014 ACR/ARHP Annual Meeting

    Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population

    Brian Sauer1, Chia-Chen Teng1, Tao He1, Jianwei Leng2, Chao-Chin Lu1, Neel Shah3, David J. Harrison4, Derek Tang4 and Grant W. Cannon5, 1Salt Lake City VA and University of Utah, Salt Lake City, UT, 2Salt Lake City VA and University of Utah, Salt Lake Citty, UT, 31 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, 4Amgen Inc., Thousand Oaks, CA, 5Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT

    Background/Purpose: Biologics used for rheumatoid arthritis (RA) and ankylosing spondylitis (AS), including tumor necrosis factor blockers, are a key area of focus for Veterans Affairs…
  • Abstract Number: 1514 • 2014 ACR/ARHP Annual Meeting

    An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations

    M.E. Dowty, T.S. Lin, L. Wang, J. Jussif, B. Juba, L. Li, E. Moy and J.-B. Telliez, Pfizer Worldwide R&D, Cambridge, MA

    Background/Purpose: A number of Janus kinase (JAK) inhibitors are being actively investigated for treatment of rheumatoid arthritis (RA), including tofacitinib, baricitinib, filgotinib (GLPG0634), and decernotinib…
  • Abstract Number: 1485 • 2014 ACR/ARHP Annual Meeting

    Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study

    Joel M. Kremer1, Gerd Burmester2, Michael Weinblatt3, Angela Williams4, Niklas Karlsson5, Alex Godwood6 and David Close7, 1Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 2Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 3Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 4MedImmune Ltd, Cambridge, United Kingdom, 5Health Economics and Outcomes Research, AstraZeneca, Molndal, Sweden, 6Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, 7Clinical Development, MedImmune Ltd, Cambridge, United Kingdom

    Background/Purpose Active RA significantly impairs health-related quality of life (HRQoL) and physical function of patients. Granulocyte-macrophage colony-stimulating factor (GM-CSF) plays a key role in macrophage…
  • Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting

    Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting

    Yomei Shaw1, Chung-Chou H. Chang2, Marc C. Levesque3, Julie M. Donohue4, Kaleb Michaud5,6 and Mark S. Roberts1, 1Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 2Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 3Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 4Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 5National Data Bank for Rheumatic Diseases, Wichita, KS, 6Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…
  • Abstract Number: 2923 • 2014 ACR/ARHP Annual Meeting

    Protein Quantification Using Mass Spectrometry Methods to Predict Response to Abatacept and Methotrexate Combination Therapy in Rheumatoid Arthritis

    A Obry1,2, P Cosette2, T Lequerré1,3, Maria-Antonietta d'Agostino4, C Gaillez5, M Le Bars6 and O Vittecoq1,3, 1Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 2UMR 6270 CNRS, PISSARO Proteomic Facility, IRIB, Normandy University, University of Rouen, Rouen, France, 3Department of Rheumatology, Rouen University Hospital, Rouen, France, 4AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, 5Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, 6Bristol-Myers Squibb, Rueil-Malmaison, France

    Background/Purpose: Targeted biologic therapies with different mechanisms of action are commonly used in RA. Abatacept is a recombinant fusion protein that inhibits T-cell co-stimulatory molecules…
  • Abstract Number: 1407 • 2014 ACR/ARHP Annual Meeting

    Low HAQ and Pain Predict Patient Perceived Remission in Rheumatoid Arthritis Patients Receiving MTX or Anti-TNF-Alpha Treatment

    Paul Studenic1, Josef Smolen2 and Daniel Aletaha1, 1Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Medicine 3, Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria

    Background/Purpose The induction of remission is the primary target of RA therapy. Failing to achieve the patient global estimate of disease activity criterion (PGA
  • Abstract Number: 2912 • 2014 ACR/ARHP Annual Meeting

    Impact of Failure to Adhere to Treat-to-Target of Rheumatoid Arthritis in Real World Practice: Data from the International Rheumatoid Arthritis Biomarker Program

    Walter P. Maksymowych1,2, M. Østergaard3, O Elkayam4, R Landewé5, J Homik6, C Thorne7, M Backhaus8, S Shaikh9, G Boire10, M Larche11, B Combe12, T Schaeverbeke13, A Saraux14, G Ferraccioli15, M Dougados16, C Barnabe17, M Govoni18, PP Tak19, D. van Schaardenburg20, D van der Heijde21, R Dadashova2, E Hutchings2, J Paschke2 and Oliver FitzGerald22, 1Medicine, University of Alberta, Edmonton, AB, Canada, 2CaRE Arthritis, Edmonton, AB, Canada, 3Copenhagen Center for Arthritis Research, Glostrup, Denmark, 4Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 5Amsterdam Rheumatology Center, Amsterdam, Netherlands, 6University of Alberta, Edmonton, AB, Canada, 7Southlake Regional Health Centre, Newmarket, ON, Canada, 8Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, 9Niagara Peninsula Arthritis Centre, Hamilton, ON, Canada, 10CHUS-Sherbrooke University, Sherbrooke, QC, Canada, 11St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 12Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 13Bordeaux University Hospital, Bordeaux, France, 14CHU Brest and EA 2216, UBO, Brest, France, 15Catholic University of The Sacred Heart, Rome, Italy, 16Hopital Cochin, Paris, France, 17University of Calgary, Calgary, AB, Canada, 18Universita di Ferrara, Ferrara, Italy, 19Academic Medical Center, Amsterdam, Netherlands, 20Jan van Breemen Research Institute, Amsterdam, Netherlands, 21Leiden University Medical Center, Leiden, Netherlands, 22St. Vincent's University Hospital, Dublin, Ireland

    Background/Purpose . There is limited data on adherence to treat-to-target (T2T) strategies in RA in real world-practice and the impact of failure to adopt this…
  • Abstract Number: 1384 • 2014 ACR/ARHP Annual Meeting

    Fibromyalgia and Its Effect on Treatment Response in Early Rheumatoid Arthritis Patients  

    Josefina Durán Santa Cruz1, Bernard Combe2, Jingbo Niu1, Nathalie Rincheval3, Cécile Gaujoux-Viala4 and David T. Felson5, 1Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 2Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 3Institut Universitaire de Recherche Clinique, Montpellier, France, 4EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, 5Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: Fibromyalgia (FM) occurs commonly in patients with rheumatoid arthritis (RA) and its effect on treatment response is unknown. In this study we aimed to…
  • Abstract Number: 2663 • 2013 ACR/ARHP Annual Meeting

    Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice

    Jos Hendrikx1, Jaap Fransen2, Alessandro Toniolo3 and Piet L.C.M. van Riel4, 1Rheumatology (470), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Pfizer Pharmaceuticals, Rome, Italy, 4Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Several Patient Reported Outcome (PRO)-based instruments to measure disease activity in Rheumatoid Arthritis (RA) exist,  though an evidence base for their use in monitoring…
  • Abstract Number: 1797 • 2013 ACR/ARHP Annual Meeting

    A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis

    Monica Luchi, Rosanne Fidelus-Gort, Diane Douglas, Haifeng Zhang, Robert Flores, Robert Newton, Peggy Scherle, Swamy Yeleswaram, Xuejun Chen and Victor Sandor, Incyte Corporation, Wilmington, DE

    Background/Purpose: To characterize the safety and efficacy of INCB039110, a novel and selective JAK1 inhibitor, in patients with active RA. Methods: This phase 2, multicenter…
  • Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting

    Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial

    P.H.P. de Jong1, A.E.a.M. Weel2, J.J. Luime3, P.J. Barendregt2, A.H. Gerards4, P.A. van der Lubbe4, M.H. de Jager5, P.B. de Sonnaville6, D. van Zeben7, B.A. Grillet8 and J.M.W. Hazes3, 1Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 3Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 4Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, 5Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, 6Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 7Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 8Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and  maintained with less treatment…
  • Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting

    Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice

    Gabriela Ávila1, Sara Marsal1, Arnald Alonso1, Carolina Diaz2, Estefanía Quesada-Masachs2, María López-Lasanta1 and Isabel Acosta3, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, 3Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology